Delivery Order SPE2DB24D2003-SPE2DB25FXML8
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,492.36 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of August 8, 2025, one day following the August 7, 2025 award date. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor on this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,322.33 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Rexulti (brexpiprazole) 1 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,697.80 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026....
- The Defense Logistics Agency awarded a $4,729.87 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 1 mg on August 12, 2025, with completion scheduled for August 13, 2025. This competitive award utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $23,256.95 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. This non-set-aside award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a pharmaceutical delivery to support federal medical procurement needs. The contract is executed from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Rexulti 1 mg tablets (30-count packages) under a firm fixed-price contract valued at $5,508.44, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order for a pharmaceutical product commonly prescribed for psychiatric conditions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Rexulti 1 mg tablets (30-count) valued at $5,894.80 under a firm fixed-price contract, with performance through August 21, 2025. This non-set-aside award was issued on August 20, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. Rexulti (brexpiprazole) is an atypical antipsychotic medication used in treating schizophrenia and major depressive disorder, reflecting DLA's...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXML8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Rexulti 2 mg tablets (30-count) with a ceiling value of $14,661.08 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which has a total potential value of $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for the Defense Health Agency and federal military healthcare systems through the DLA's Medical Supply Chain. The SPE2DX IDC functions as a comprehensive global pharmaceutical support vehicle, enabling the company to supply an extensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Rexulti (brexpiprazole) is an antipsychotic medication used in treating depression and schizophrenia, representing one of numerous pharmaceutical products delivered under this prime contract vehicle to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.7k | 9/8/25 |